NHL | Jotup

Why luck plays such a big role in hockey

Retrieved on:

星期四, 四月 18, 2024

Finger, Bruise, NHL, Baseball, Ice, NBA, Hockey, Probability, Travel, Football, Sport, Sports equipment

In the NHL, it is estimated that the contribution of luck to a team’s season record is approximately 53%.

Key Points:

In the NHL, it is estimated that the contribution of luck to a team’s season record is approximately 53%.
The more chances a team has, the less luck plays a role in the outcome.
Luck plays much more of a role when the opportunities to score are lower.
Deflect, deflect, deflect
The outsize role of luck in hockey can also be explained by an additional factor.

New Jersey Devils and Prudential Center announce extended partnership with Verizon

Retrieved on:

星期二, 四月 9, 2024

Wireless network, Verizon Communications, Prudential Center, New Jersey Devils, Network, Verizon Business, Partnership, Prudential, Senior ice hockey, Power, National Hockey League, SVP, RSS, Food, NHL, VZ, Hockey, Beer, Mobile phone

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- The New Jersey Devils, Prudential Center, and Verizon announced today a multi-year extension of their partnership featuring new and innovative technology for wireless connectivity and retail convenience to enhance the fan experience and improve arena operations.

Key Points:

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- The New Jersey Devils, Prudential Center, and Verizon announced today a multi-year extension of their partnership featuring new and innovative technology for wireless connectivity and retail convenience to enhance the fan experience and improve arena operations.
Through this extended partnership, Verizon is deploying Verizon 5G Ultra Wideband, Verizon Private 5G Network and Wi-Fi 6/6E to give Prudential Center the ability to host a wide range of large-scale events, concerts and games with a more efficient and reliable network and fast connectivity.
The improved wireless connectivity will also change the way fans experience games and live events in the arena and through the Devils and Prudential Center Mobile App, Powered by Verizon.
“We are thrilled to extend our partnership with Verizon, a New Jersey-based company, and lay the foundation for the way fans view and experience Devils home games and other events at Prudential Center,” said Sasha Puric, Chief Technology Officer, HBSE.

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Retrieved on:

星期二, 四月 9, 2024

SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of the first findings of clinical responses in the brain for NX-5948, an orally available, selective degrader of Bruton’s tyrosine kinase (BTK). The presentation included case studies for two patients, one with CLL with CNS involvement and the other with PCNSL, each demonstrating clinically meaningful responses. The presentation also provided evidence of measurable drug levels in the CNS of multiple patients in the ongoing Phase 1 trial who had CNS tumor involvement. These data were presented by Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, as part of the Major Symposium session Molecular Glues, PROTACs, and Next-Gen Degraders: Discovery and Early Preclinical Advances at the AACR 2024 Annual Meeting, which is being held from April 5-10, 2024, in San Diego, CA.

Key Points:

The presentation included case studies for two patients, one with CLL with CNS involvement and the other with PCNSL, each demonstrating clinically meaningful responses.
The presentation also provided evidence of measurable drug levels in the CNS of multiple patients in the ongoing Phase 1 trial who had CNS tumor involvement.
“These data are the first demonstration of clinical activity in the brain of a targeted protein degrader, opening the door for new therapeutic strategies to treat leukemias and lymphomas with CNS involvement,” said Dr. Hansen.
“The CLL patient with CNS involvement showed an impressive durable response with NX-5948 as single agent therapy in this setting.

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Retrieved on:

星期一, 四月 8, 2024

Principal, Malignancy, Risk, Patient, Food and Drug Administration, City, CRS, NHL, Mutagenesis, Therapy, Hematology, Bone marrow, B-cell lymphoma, APOLLO, Neurotoxicity, DLBCL, Cytokine release syndrome, Lymphoma, Press release

HOUSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada (April 2-7, 2024). Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.

Key Points:

Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.
During the presentation, Dr. Shouse showed that this study participant remains in CR nine months following initial treatment with MT-601.
This APOLLO participant had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including anti-CD19 CAR T cell therapy.
Dr. Shouse’s presentation included data from two additional study participants that have been treated at City of Hope.

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Retrieved on:

星期四, 四月 4, 2024

Symantec Endpoint Protection, CLL, Safety, RT, Patient, EBMT, NHL, Euronext, Efficacy, Abstract, CD19, Pharmaceutical industry

ATALANTA-1 and EUPLAGIA-1 are ongoing Phase 1/2 open-label, multi-center studies designed to assess the safety, efficacy and feasibility of point-of-care manufactured GLPG5101 and GLPG5201 in patients with relapsed/refractory NHL, and relapsed/refractory CLL and RT, respectively.

Key Points:

ATALANTA-1 and EUPLAGIA-1 are ongoing Phase 1/2 open-label, multi-center studies designed to assess the safety, efficacy and feasibility of point-of-care manufactured GLPG5101 and GLPG5201 in patients with relapsed/refractory NHL, and relapsed/refractory CLL and RT, respectively.
The primary objective of the Phase 1 part of the studies is to evaluate the safety and preliminary efficacy to determine the recommended dose for the Phase 2 part of the study.
GLPG5101 and GLPG5201 are second generation anti-CD19/4-1BB CAR-T product candidates, administered as a single fixed intravenous dose.
“We are committed to accelerating breakthrough innovations to extend the reach of CAR-T therapies to patients with rapidly progressing cancers,” said Dr. Jeevan Shetty, M.D., Head of Clinical Development Oncology at Galapagos.

Gray Television’s BEAT THE ODDS and SportsGrid Launch Partnership for National Syndication of Five Sports Betting Specials

Retrieved on:

星期二, 四月 2, 2024

Honey, Growth, Ted, Sport, Superbook, Golf, Dan Abrams, College, Association football, KVVU, News, NHL, Tupelo, MLB, Injury, NBA, BEAT, NFL, Television, Casino

The specials will be part of the “BEAT THE ODDS” nationally syndicated sports betting and entertainment television series produced by Tupelo Media Group and KVVU.

Key Points:

The specials will be part of the “BEAT THE ODDS” nationally syndicated sports betting and entertainment television series produced by Tupelo Media Group and KVVU.
The specials begin this weekend for college basketball and will also air on dozens of Gray’s television stations.
BEAT THE ODDS’ special coverage will feature breaking news, information and expert gambling analysis from five major sporting events in 2024.
The SuperBook at the Westgate Las Vegas Resort and Casino will be the title sponsor for these BEAT THE ODDS specials.

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Retrieved on:

星期四, 三月 28, 2024

WORCESTER, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced its expansion into autoimmune diseases with MB-106, a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”). Mustang and Fred Hutch are in preliminary discussions to explore a potential Phase 1 investigator-sponsored clinical trial to evaluate MB-106 for the treatment of autoimmune diseases.

Key Points:

MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”).
Mustang and Fred Hutch are in preliminary discussions to explore a potential Phase 1 investigator-sponsored clinical trial to evaluate MB-106 for the treatment of autoimmune diseases.
“MB-106’s observed safety profile, encouraging efficacy data, and our robust manufacturing capabilities have the potential to translate to improved outcomes for patients with autoimmune diseases.
Several antibody therapies targeting CD20 on B-cells have successfully transitioned from cancer to autoimmune diseases, such as rituximab for both lymphoma and rheumatoid arthritis.

iVirtual and Saige Consulting Partner to Launch FanMore™ to Transform how Teams Connect with Fans

Retrieved on:

星期二, 四月 9, 2024

iVirtual and Saige Consulting (Saige) today announced their partnership on the creation of FanMore ™, a groundbreaking new fan rewards platform.

Key Points:

iVirtual and Saige Consulting (Saige) today announced their partnership on the creation of FanMore ™, a groundbreaking new fan rewards platform.
Connecting fans with teams and teams with fan insights, FanMore engages and captures the unseen 90% of fans who are not able to attend games in-person, building revenue channels for teams and engagement channels for sponsors.
We built FanMore to connect fans with teams, and teams with fan insights,” said Meghan Nameth, Co-Founder of iVirtual.
The product confronts the multifaceted challenges teams face when looking to expand their connection with their fans,” said Charles Hu, Senior Partner, Technology, Saige.

Harvey's named the Official Hamburger of the National Hockey League in Canada

Retrieved on:

星期二, 四月 9, 2024

Vanilla, Harvey, Partnership, Senior ice hockey, Harvey's, National Hockey League, NHL, Stanley Cup playoffs, Stanley Cup Finals, Chocolate, Hockey

VAUGHAN, ON, April 9, 2024 /CNW/ - Harvey's announced a Canadian partnership today with the National Hockey League (NHL®), naming the Canadian burger brand the Official Hamburger of the NHL in Canada.

Key Points:

VAUGHAN, ON, April 9, 2024 /CNW/ - Harvey's announced a Canadian partnership today with the National Hockey League (NHL®), naming the Canadian burger brand the Official Hamburger of the NHL in Canada.
This is the second year the two iconic brands are partnering during the Stanley Cup® Playoffs to raise awareness of two Canadian classics – Harvey's burgers and the beautiful game of hockey.
"This partnership allows us to reach guests across the country, especially as we celebrate 65 years of topping your burger, your way."
To enter, guests can visit a Harvey's restaurant and purchase their favourite item or by ordering on the Harvey's app.

INDUSTRY LEADERS CONVENE TO SHINE SPOTLIGHT ON LATINOS IN SPORTS

Retrieved on:

星期一, 四月 8, 2024

Pérez Art Museum Miami, Hispanic, Culture, Growth, Woman, Partnership, CNBC, Arizona Coyotes, Research, History, Chelsea F.C., NHL, Nike (company), Commerce, Marketing, Warner Bros. Discovery

MIAMI, April 8, 2024 /PRNewswire/ -- Seasoned executives from the worlds of sports, media, and marketing announced today a joint venture focused on the power of Latinos in the global sports industry. The multitiered platform will focus on content, careers, and convenings, and officially launch during Miami's Formula 1 weekend at a star-studded event presented by Amerant Bank and in partnership with CNBC. Through his company ImpactX Sports Group, Xavier A. Gutierrez—president and CEO of the Arizona Coyotes NHL club and the only Latino currently leading a major American sports team—created the venture with Pedro A. Guerrero—CEO of Guerrero and publisher of Hispanic Executive, the leading English language media brand highlighting Hispanic business leadership. For more information, visit www.LatinosInSports.com.

Key Points:

"Sports are critically important to culture, commerce, and community; and by any measure Latinos are driving the future growth of this industry," said Gutierrez, Founder of ImpactX Sports Group.
"There is a dearth of impactful events, content, and research shining a spotlight on these trendlines, and Pedro is the perfect partner to join me in filling that void."
Following the event, the group will roll out a digital content platform, proprietary research studies, thought leadership initiatives, and career resources for current and aspiring Latino executives in the sports industry.
"The Latino community is the driving engine of the American economy, and sports is a thriving industry where Latinos are leading both on the field and in the executive ranks," said Guerrero, publisher of Hispanic Executive.